

HRT Treatment Selector

Charts reviewed October 2018. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF	
Estradiol	↓ ^a	↓ ^a	↓ ^a	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑	
Progestins (HRT)	Drospirenone	↑ ^b	↑ ^b	↑ ^b	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^b	↑ ^b
	Dydrogesterone	↑ ^b	↑ ^b	↑ ^b	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^b	↑ ^b
	Levonorgestrel	↑ ^b	↑ ^b	↑ ^b	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^b	↑ ^b
	Medroxy-progesterone (oral)	↑ ^b	↑ ^b	↑ ^b	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^b	↑ ^b
	Norethisterone (Norethindrone)	↑ ^b	↑ ^b	↑ ^b	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^b	↑ ^b
	Norgestrel	↑ ^b	↑ ^b	↑ ^b	↓ ^a	↓ ^a	↓ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^b	↑ ^b

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the hormone
- ↓ Potential decreased exposure of the hormone
- ↔ No significant effect

- a Monitor for signs of estrogen deficiency.
- b The clinical significance of increased progestin exposure in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown.